Hormonal predictors of prostate cancer: A meta-analysis

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 847-853

  Shaneyfelt, Terrence ^a   Husein, Rozita ^a   Bubley, Glenn ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 OXOSTEROID; ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; BOLDENONE; CORTICOSTEROID; ESTRADIOL; PRASTERONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; META ANALYSIS; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

EID: 0033983034     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.847     Document Type: Article

References (50)

1. van Steenbrugge GJ, Schroder FH: Androgen-dependent human prostate cancer in nude mice: The PC-82 tumor model. Am J Clin Oncol 11: S8-12, 1988 (suppl 2)
2. Smolev JK, Coffey DS, Scott WW: Experimental models for the study of prostatic adenocarcinomas. J Urol 118:216-220, 1977
3. Henderson BE, Ross BK, Pike MC, et al: Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232-3239, 1982
4. Hsing AW: Hormones and prostate cancer: Where do we go from here? J Natl Cancer Inst 88:1093-1095, 1996
5. Nomura AM, Kolonel LN: Prostate cancer: A current perspective. Epidemiol Rev 13:200-207, 1991
6. Andersson SO, Adami H-O, Bergstrom R, et al: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer: A population based case-control study. Br J Cancer 68:97-102, 1993
7. Meikle AW, Smith JA, Stringham JD: Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 10:25-31, 1987
8. Hsing AW, Comstock GW: Serological precursors of cancer: Serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2:27-32, 1993
9. Nomura A, Heilbrun LK, Stemmermann GN, et al: Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48:3515-3517, 1988
10. Barrett-Connor E, Garland C, McPhillips JB, et al: A prospective, population based study of androstendione, estrogens and prostatic cancer. Cancer Res 50:169-173, 1990
11. Gann PH, Hennekens CH, Ma J, et al: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118-1126, 1996
12. Nomura A, Stemmermann GN, Chyou P-A, et al: Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 5:621-625, 1996
13. Chan J, Stampfer M, Giovannucci E, et al: Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 279:563-566, 1998
14. Mantzoros C, Tzonou A, Signorello L, et al: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118, 1997
15. Wolk A, Mantzoros C, Anderson S-O, et al: Insulin-like growth factor 1 in relation to prostate cancer: A population-based case-control study in Sweden. J Natl Cancer Inst 90:911-915, 1998
16. Comstock GW, Gordon GB, Hsing AW: The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 2:219-221, 1993
17. Guess HA, Friedman GD, Sadler MC, et al: 5-alpha reductase activity and prostate cancer: A case-control study using stored sera. Cancer Epidemiol Biomarkers Prev 6:21-24, 1997
18. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trial 7:177-188, 1986
19. Gustafsson O, Norming U, Gustaffson S, et al: Dihydrotestosterone and testosterone levels in men screened for prostate cancer: A study of a randomized population. Br J Urol 77:433-440, 1996
20. Carlstrom K, Stege R: Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls. Br J Urol 79:427-431, 1997
21. Ahluwalia B, Jackson MA, Jones GW, et al: Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 48:2267-2273, 1981
22. Bartsch W, Steins P, Becker H: Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation. Eur Urol 3:47-52, 1977
23. Bartsch W, Horst HJ, Becker H, et al: Sex hormone binding globulin capacity, testosterone, 5-alpha dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol 85:650-664, 1977
24. Drafta D, Proca E, Zamfir V, et al: Plasma steroids in benign hypertrophy and carcinoma of the prostate. J Steroid Biochem 17:689-693, 1982
25. Ghanadian R, Puah CM, O'Donoghue EPN: Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39:696-699, 1979
26. Hammond G, Kontturi M, Vihko P, et al: Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 9:113-121, 1978
27. Harper ME, Peeling WB, Cowley T, et al: Plasma steroid and protein hormone concentrations in patients with prostate cancer before and during oestrogen therapy. Acta Endocrinol 81:409-426, 1976
28. Hill P, Wynder EL, Garbaczewski L, et al: Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res 42:3864-3869, 1982
29. Hoisaeter PA, Haukaas S, Bakke A, et al: Blood hormone levels related to stages and grades of prostatic cancer. Prostate 3:375-381, 1982
30. Hsing A, Comstock G: Serum hormone and risk of subsequent prostate cancer. Am J Epidemiol 130:829, 1989 (abstr)
31. Hulka BS, Hammond JE, Difernando G, et al: Serum hormone levels among patients with prostatic carcinoma or benign prostatic hypertrophy and clinic controls. Prostate 11:171-182, 1987
32. Jackson MA, Kovi J, Heshmat MY, et al: Characterization of prostatic carcinoma among blacks: A comparison between a low-incidence area, Ibadan, Nigeria, and a high-incidence area, Washington, DC. Prostate 1:185-205, 1980
33. Jacobi GH, Rathgen GH, Altwein JE: Serum prolactin and tumors of the prostate: Unchanged basal levels and lack of correlation to serum testosterone. J Endocrinol 3:15-18, 1980
34. Levell MJ, Rowe E, Glashan RW, et al: Free testosterone in carcinoma of the prostate. Prostate 7:363-367, 1985
35. Meikle AW, Stanish W: Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metabol 54:1104-1108, 1982
36. Meikle AW, Smith JA, Stringham JD: Estradiol and testosterone metabolism and production in men with prostatic cancer. J Steroid Biochem 33:19-24, 1989
37. Ranikko FS, Adlercreutz H: Plasma estradiol, free testosterone, sex hormone binding globulin capacity and prolactin in benign prostatic hyperplasia and prostate cancer. Prostate 4:223-229, 1983
38. Ross R, Bernstein L, Lobo R, et al: 5-Alpha reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339:887-889, 1992
39. Saroff J, Kirdani RY, Chu TM, et al: Measurements of prolactin and androgens in patients with prostatic diseases. Oncology 37:46-52, 1980
40. Zumoff B, Levin J, Strain GW, et al: Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a "two-disease" theory. Prostate 3:579-588, 1982
41. Montie JE, Pienta K: Review of the role of androgenic hormones in the epidemiology of prostate cancer and benign prostatic hyperplasia. Urology 43:892-898, 1994
42. Santner SJ, Albertson B, Zhang G-Y, et al: Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 83:2104-2109, 1998
43. Wilson JD: The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog Horm Res 26:309-336, 1990
44. Geller J: Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab 80:717-719, 1995
45. Cohen P, Peehl DM, Lamson G, et al: Insulin like growth factors (IGF), IGF receptors and IGF binding proteins in primary culture of prostate epithelial cells. J Clin Endocrinol Metab 73:401-407, 1991
46. Kimura G, Kasuaya J, Giannini S, et al: Insulin like growth factor (IGF) system components in human prostatic cancer cell lines: LnCaP, DU 145, PC-3 cells. Int J Urol 3:39-46, 1996
47. Pietrzkowski Z, Mulholand G, Gomella L, et al: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106, 1993
48. Angelloz-Nicoud P, Binoux M: Autocrine regulation of cell proliferation by the insulin like growth factor (IGF) and IGF binding protein 3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136:5485-5492, 1995
49. Burfeind P, Chernicky CL, Rininsland F, et al: Antisense RNA to the type insulin like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 93:7263-7268, 1996
50. Culig Z, Hobish A, Cronauer MV, et al: Androgen receptor activation of prostatic tumor cell lines by insulin like growth factor 1, keratinocyte growth factor and epidermal growth factor. Eur Urol 27:45-47, 1995 (suppl 2)